Pharma Packaging and Labelling Compliance Conference

Fleming Europe23 - 25 March 2011, Barcelona, Spain.
As pharmaceutical and patient landscape is constantly developing worldwide, excellence in strategic packaging and labelling has become essential to regulatory compliance, patient adherence, safety and sustainability.

Fleming Europe has selected from across the globe the highest-level pharmapack specialists, who will share their many market-specific local interpretations, which will influence pharmaceutical packaging and labelling structurally in 2011.

Listen to them speaking about the latest regulations coming into effect in the next months (including PharmaBraille and 2D Datamatrix Marking System). Discover various ways of patient adherence and the business models of in-house vs. outsourced artwork management. Be part of interactive roundtables focusing on the most advanced technologies of pharmapack traceability.…and listen to real-life case studies of anti-counterfeiting, parallel trade and packaging sustanability.

This 3-Day-Event includes a target audience focused post-conference workshop in 2 streams, which will bring together innovative, responsible and cost-effective methods of pharmaceutical and medical packaging, addressing key labelling issues as well as creating partnerships between industry leaders.

Key speakers:

  • Executive Director, Healthcare Compliance Packaging Council (HCPC), Austria
  • Director, Global Regulatory Affairs Strategic Policy & Support, Johnson&Johnson, UK
  • Secretary General, Child-Safe Packaging Group, UK
  • Head of Packaging Strategy, Global Pharma Operations, Novartis, Switzerland
  • Head of Patient Information Quality, MHRA, UK
  • Director of Materials and Packaging Quality System, Eli Lilly, USA
  • Director of Healthcare Traceability, GS1 Global, UK
  • Head of Pharmacy Trade Sector, Roche Diagnostics, Germany

Key topics:

  • Packaging & Labelling Regulatory Updates
  • Patient Adherence
  • Excellence in Artwork Management: In-house vs. Outsourced
  • Traceability to Combat Non-compliance
  • Packaging suitable for the Blind – Braille-Guidelines according to the European standards implemented from October 2010
  • Innovative 2D Datamatrix System for Pharma Traceability
  • Anti-Counterfeiting using Advanced Technology
  • Parallel Traders Perspectives
  • Sustainable Packaging Innovations
  • Child-safe vs. Senior friendly Packaging – Balancing Patients’ Needs
  • Information based Packaging Redesign

Who should attend:
VPs, Directors, Heads and Managers of Packaging, Labelling, Supply Chain and Logistics, Regulatory Affairs and Compliance, Quality Assurance, Product Information, Product Development, Operations, Quality Control and Assurance, Licensing, Marketing and Sales, Patient Compliance, Purchase / Facilities, Manufacturing Technology, International Labelling Liaison, Packaging Designer, Global Labelling.

For further information and registration, please visit:
http://www.flemingeurope.com/life-science-conferences/europe/pharma-packaging-and-labelling-compliance-conference

About Fleming Europe conferences
Fleming Europe conferences are events linking business with intelligence. Carefully designed to provide key strategic business information and the best networking opportunities for the participants, our B2B conferences are highly interactive. Number of delegates from specialized industry sectors - brought together by Fleming Europe - become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]